Glial cells as therapeutic targets in progressive multiple sclerosis

References

• Rotstein DL, Chen H, Wilton AS, et al. Temporal trends in multiple sclerosis prevalence and incidence in a large population. Neurology. 2018;90:1535-1441.
   PubMedGoogle Scholar
• Dilokthornsakul P, Valuck RJ, Nair KV, et al. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014–1021.
   PubMed Web of Science ®Google Scholar
• Gilmour H, Ramage-Morin PL, Wong SL. Multiple sclerosis: prevalence and impact. Heal Reports. 2018;29:3–8.
   Web of Science ®Google Scholar
• Goldenberg MM. Multiple sclerosis review. Pharmacol Ther. 2012;37:175–184.
   Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173.
   PubMed Web of Science ®Google Scholar
• Fred D, Lublin M, Stephen C, et al. Defining the clinical course of multiple sclerosis the 2013 revisions. Neurology. 2014;83:278–286.
   PubMed Web of Science ®Google Scholar
• McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913–919.
   PubMed Web of Science ®Google Scholar
• Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropathol. 2011;9:409–416.
   Google Scholar
• Lucchinetti CF, Rodriguez M. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Mayo Clin Proc. 1997;72:665–678.
   PubMed Web of Science ®Google Scholar
• Winger RC, Zamvil SS. Antibodies in multiple sclerosis oligoclonal bands target debris. Proc Natl Acad Sci. 2016;113:7696–7698.
   PubMed Web of Science ®Google Scholar
• Dobson R, Ramagopalan S, Davis A, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84:909–914.
   PubMed Web of Science ®Google Scholar
• Loleit V, Biberacher V, Hemmer B. Current and future therapies targeting the immune system in multiple sclerosis. Curr Pharm Biotechnol. 2014;15:276–296.
   PubMed Web of Science ®Google Scholar
• Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778–809.
   PubMed Web of Science ®Google Scholar
• Pestka S, Langer JA. Interferons and their actions. Annu Rev Biochem. 1987;5656:727727–777777.
   Google Scholar
• Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol. 2001;112:153–162.
   PubMed Web of Science ®Google Scholar
• Burdin N, Van Kooten C, Galibert L, et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol. 1995;154:2533–2544.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, et al. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by Monocytes. 1991;174:1209-1220.
   Google Scholar
• Mayr WT, Pittock SJ, McClelland RL, et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology. 2003;61:1373–1377.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Medical progress: multiple sclerosis. N Engl J Med. 2000;343:938–952.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285–294.
   PubMed Web of Science ®Google Scholar
• Paty DW, Li D. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. Neurology. 1993;43:662–667.
   Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453–1460.
   PubMed Web of Science ®Google Scholar
• Fischer JS, Priore RL JL, Jacobs LD, et al. Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. multiple sclerosis collaborative research group. Ann Neurol. 2000;48:885–892.
   PubMed Web of Science ®Google Scholar
• Goodin D, Frohman E, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Neurology. 2007;68:977–984.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 1998;50:1294–1300.
   PubMed Web of Science ®Google Scholar
• Neilley LK, Goodin DS, Goodkin DE, et al. Side effect profile of interferon beta-lb in MS: results of an open label trial. Neurology. 1996;46:552–553.
   PubMed Web of Science ®Google Scholar
• Walther EU, Hohlfeld R. Multiple Slecrosis: side effects of interferon beta therapy and their management. Neurology. 1999;53:1622–1627.
   PubMed Web of Science ®Google Scholar
• Goeb JL, Even C, Nicolas G, et al. Psychiatric side effects of interferon-β in multiple sclerosis. Eur Psychiatry. 2006;21:186–193.
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Farina C, Wekerle H, et al. Mechanisms of action of glatiramer. Nuerology. 2001;56:702–708.
   PubMed Web of Science ®Google Scholar
• Gran B, Tranquill L, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 2000;55:1704–1714.
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16:342–350.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14–24.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 1998;50:701-708.
   Google Scholar
• Pöllmann W, Erasmus LP, Feneberg W, et al. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology. 2002;59:636–639.
   PubMed Web of Science ®Google Scholar
• Warnke C, Zu Hörste GM, Hartung HP, et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333–340.
   PubMed Web of Science ®Google Scholar
• Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124:75–84.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–1303.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883–897.
   PubMed Web of Science ®Google Scholar
• Suzanne M, Richard H, James B, et al. Alteration of lymphocyte trafficking by sphingosine- 1-phosphate receptor agonists. Science. 2002;296:346–349.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355–360.
   PubMed Web of Science ®Google Scholar
• Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323:469–475.
   PubMed Web of Science ®Google Scholar
• Comi G, O’Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16:197–207.
   PubMed Web of Science ®Google Scholar
• Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10:520–529.
   PubMed Web of Science ®Google Scholar
• Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci. 2016;113:4777–4782.
   PubMed Web of Science ®Google Scholar
• Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:1–10.
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678–692.
   PubMed Web of Science ®Google Scholar
• Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2:103–118.
   PubMed Web of Science ®Google Scholar
• Yednock T, Cannon C, Fritz L, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin. Nature. 1992;356:63–66.
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2004;351:1493–1501.
   PubMedGoogle Scholar
• Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9:44–52.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–1787.
   PubMed Web of Science ®Google Scholar
• Emery P, Rigby W, Tak PP, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014;9:8.
   Google Scholar
• Smith PJ, Morgan SA, Fox ME, et al. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol. 1990;40:2069–2078.
   PubMed Web of Science ®Google Scholar
• Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006;28:461–474.
   PubMed Web of Science ®Google Scholar
• Olindo S, Gullion B, Helias J, et al. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol. 2002;9:287–291.
   PubMed Web of Science ®Google Scholar
• Senaratne MPJ, Carroll D, Warren KG, et al. Evidence for cardiovascular autonomic nerve dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1984;47:947–952.
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Wolf A, Krauser M, et al. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol. 1999;246:578–586.
   PubMed Web of Science ®Google Scholar
• Issacs ALJ. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258–267.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. J Fur Neurol Neurochir Psychiatr. 2017;18:30–31.
   Google Scholar
• Aloisi F. Immune function of microglia. Glia. 2001;36:165–179.
   PubMed Web of Science ®Google Scholar
• Husemann J, Loike JD, Anankov R, et al. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia. 2002;40:195–205.
   PubMed Web of Science ®Google Scholar
• Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol. 2010;119:89–105.
   PubMed Web of Science ®Google Scholar
• Kierdorf K, Prinz M. Factors regulating microglia activation. Front Cell Neurosci. 2013;7:1–8.
   PubMed Web of Science ®Google Scholar
• Chu F, Shi M, Zheng C, et al. The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018;318:1–7.
   PubMed Web of Science ®Google Scholar
• Wu Y, Dissing-Olesen L, Macvicar BA, et al. Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol. 2016;36:605–613.
   Google Scholar
• Luo C. The role of microglia in multiple sclerosis. Neuropsychiatr Dis Treat. 2017;13:1661–1667.
   Google Scholar
• Chastain EML, Duncan DS, Rodgers JM, et al. The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta - Mol Basis Dis. 2011;1812:265–274.
   PubMed Web of Science ®Google Scholar
• Kielian T, Mayes P, Kielian M. Characterization of microglial responses to Staphylococcus aureus: effects on cytokine, costimulatory molecule, and Toll-like receptor expression. J Neuroimmunol. 2002;130:86–99.
   PubMed Web of Science ®Google Scholar
• Gudi V, Gingele S, Skripuletz T, et al. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci. 2014;8:1–24.
   PubMed Web of Science ®Google Scholar
• Neumann H, Kotter MR, Franklin RJM. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288–295.
   PubMed Web of Science ®Google Scholar
• Hiremath MM, Saito Y, Knapp GW, et al. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol. 1998;92:38–49.
   PubMed Web of Science ®Google Scholar
• Voß EV, Škuljec J, Gudi V, et al. Characterisation of microglia during de- and remyelination: can they create a repair promoting environment? Neurobiol. Dis. 2012;45:519–528.
   Google Scholar
• Mason JL, Ye P, Suzuki K, et al. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. Nat Commun. 2000;20:5703–5708.
   Google Scholar
• Pérez-Martín M, Cifuentes M, Grondona JM, et al. IGF-I stimulates neurogenesis in the hypothalamus of adult rats. Eur J Neurosci. 2010;31:1533–1548.
   PubMed Web of Science ®Google Scholar
• McKinnon RD, Matsui T, Dubois-Dalcq M, et al. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron. 1990;5:603–614.
   PubMed Web of Science ®Google Scholar
• Muir DA, Compston DAS. Growth factor stimulation triggers apoptotic cell death in mature oligodendrocytes. J Neurosci Res. 1996;44:1–11.
   PubMed Web of Science ®Google Scholar
• Kumar S, Biancotti J, Yamaguchi M, et al. Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. Nuerochem Res. 2007;32:783–797.
   PubMed Web of Science ®Google Scholar
• Lodge P, Sriram S. Regulation of microglial activation by TGF‐β, IL‐10, and CSF‐1. J Leukoc Biol Suppl. 1996;60:502–508.
   Google Scholar
• Sriram S, Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology. 1997;48:464–470.
   PubMed Web of Science ®Google Scholar
• Warrington AE, Asakura K, Bieber AJ, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Pnas. 2000;97:6820–6825.
   PubMed Web of Science ®Google Scholar
• Warrington AE, Bieber AJ, Ciric B, et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci. 2007;85:967–976.
   Web of Science ®Google Scholar
• Mullin AP, Cui C, Wang Y, et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis. 2017;105:142–155.
   PubMed Web of Science ®Google Scholar
• Zorina Y, Stricker J, Caggiano AO, et al. Human IgM antibody rHIgM22 promotes phagocytic clearance of myelin debris by microglia. Sci Rep. 2018;8:1–14.
   PubMed Web of Science ®Google Scholar
• Weinstein JR, Quan Y, Hanson JF, et al. IgM-dependent phagocytosis in microglia is mediated by complement receptor 3, not fc/receptor. J Immunol. 2015;195:5309–5317.
   PubMed Web of Science ®Google Scholar
• Airas L, Nylund M, Rissanen E. Evaluation of microglial activation in multiple sclerosis patients using positron emission tomography. Front Neurol. 2018;9:1–10.
   PubMed Web of Science ®Google Scholar
• Politis M, Giannetti P, Su P, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology. 2012;79:523–530.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Cadavid D, Steiner D, et al. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9:31–43.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405–415.
   PubMed Web of Science ®Google Scholar
• Mikita J, Dubourdieu-Cassagno N, Deloire MS, et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler J. 2011;17:2–15.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lund H, Parsa R, et al. Adoptive transfer of cytokine-induced immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in DBA/1 mice. Glia. 2014;62:804–817.
   PubMed Web of Science ®Google Scholar
• Tierney J, Kharkrang M, La Flamme A. Type-II activated macrophages supress the development of experimental autoimmune encephalomyelitis. Immunol Cell Biol. 2008;87:235–240.
   PubMed Web of Science ®Google Scholar
• Liao J, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17–24.
   PubMed Web of Science ®Google Scholar
• Guilluy C, Garcia-Mata R, Burridge K. Rho protein crosstalk: another social network? Trends Cell Biol. 2011;21:718–726.
   PubMed Web of Science ®Google Scholar
• Liu C, Li Y, Yu J, et al. Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS One. 2013;9:8.
   Google Scholar
• Li YH, Xie C, Zhang Y, et al. FSD-C10, a Fasudil derivative, promotes neuroregeneration through indirect and direct mechanisms. Sci Rep. 2017;7:1–17.
   PubMed Web of Science ®Google Scholar
• Yan Y, Yu J, Gao Y, et al. Therapeutic potentials of the Rho kinase inhibitor Fasudil in experimental autoimmune encephalomyelitis and the related mechanisms. Metab Brain Dis. 2018;34:377-384.
   Web of Science ®Google Scholar
• Wu M, Nissen JC, Chen EI, et al. Tuftsin promotes an anti-inflammatory switch and attenuates symptoms in experimental autoimmune encephalomyelitis. PLoS One. 2012;7.
   Web of Science ®Google Scholar
• Thompson KK, Nissen JC, Pretory A, et al. Tuftsin combines with remyelinating therapy and improves outcomes in models of CNS demyelinating disease. Front Immunol. 2018;9:1–16.
   PubMed Web of Science ®Google Scholar
• Ponath G, Park C, Pitt D. The role of astrocytes in multiple sclerosis. Front Immunol. 2018;9:1–12.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7–35.
   PubMed Web of Science ®Google Scholar
• Kofuji P, Newman EA. Potassium buffering in the central nervous system. Neuroscience. 2004;129:1045–1056.
   PubMed Web of Science ®Google Scholar
• Thrane AS, Rappold PM, Fujita T, et al. Critical role of aquaporin-4 (AQP4) in astrocytic Ca2+ signaling events elicited by cerebral edema. Proc Natl Acad Sci. 2011;108:846–851.
   PubMed Web of Science ®Google Scholar
• Nagelus EA, Otterson OP. Physiological roles of aquaporin-4 in brain. Phisiol Rev. 2013;93:1543–1562.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Saadoun S, Verkman AS. Aquaporins and cell migration. Eur J Physiol. 2008;456:693–700.
   PubMed Web of Science ®Google Scholar
• Pekny M, Pekna M. Reactive gliosis in the pathogenesis of CNS diseases. Biochim Biophys Acta - Mol Basis Dis. 2016;1862:483–491.
   PubMed Web of Science ®Google Scholar
• Yuan YM, He C. The glial scar in spinal cord injury and repair. Neurosci Bull. 2013;29:421–435.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Rempe D. Targeting astrocytes for stroke therapy. Nuerotherapeutics. 2010;7:439–451.
   PubMed Web of Science ®Google Scholar
• Haindl MT, Köck U, Zeitelhofer-Adzemovic M, et al. The formation of a glial scar does not prohibit remyelination in an animal model of multiple sclerosis. Glia. 2019;67:467-481.
   Google Scholar
• Kiray H, Lindsay SL, Hosseinzadeh S, et al. The multifaceted role of astrocytes in regulating myelination. Exp Neurol. 2016;283:541–549.
   PubMed Web of Science ®Google Scholar
• Bogler O, Wren D, Barnett SC, et al. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci U S A. 1990;87:6368–6372.
   PubMed Web of Science ®Google Scholar
• Pringle N, Collarini E, Mosely M, et al. PDGF A chain homodimers drive proliferation of bipotential (0–2A) glial progenitor cells in the developing rat optic nerve. Embo J. 1989;8:1049–1056.
   PubMed Web of Science ®Google Scholar
• Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci. 2011;108:751–756.
   PubMed Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–1084.
   PubMed Web of Science ®Google Scholar
• Bryan AM, Del Poeta M. Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol. 2018;20:1–10.
   Web of Science ®Google Scholar
• Li C, Chi X, Xie W, et al. Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor. J Neurophyisol. 2011;108:1473–1483.
   Web of Science ®Google Scholar
• Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773–783.
   PubMed Web of Science ®Google Scholar
• Giovanni G, Barkhof F, Hartung H-P, et al. APPREGIO: a placebo-controlled trial of oral laquinimod in primary progressive multiple sclerosis.Neurology. 2018;90.
   Web of Science ®Google Scholar
• Thöne J, Linker RA. Laquinimod in the treatment of multiple sclerosis: A review of the data so far. Drug Des Devel Ther. 2016;10:1111–1118.
   PubMed Web of Science ®Google Scholar
• Strassburger-Krogias K, Ellrichmann G, Krogias C, et al. Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Ther Adv Neurol Disord. 2014;7:232–238.
   PubMed Web of Science ®Google Scholar
• Galloway DA, Williams JB, Moore CS. Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation. Ann Clin Transl Neurol. 2017;4:381–391.
   PubMed Web of Science ®Google Scholar
• Kornberg M, Bhargava P, Kim P, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360:449–453.
   PubMed Web of Science ®Google Scholar
• Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol. 2014;261:1–16.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71:314–322.
   PubMed Web of Science ®Google Scholar
• Nave K-A, Werner HB. Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503–533.
   PubMed Web of Science ®Google Scholar
• Boggs JM. Myelin basic protein: a multifunctional protein. Cell Mol Life Sci. 2006;63:1945–1961.
   PubMed Web of Science ®Google Scholar
• Nadon N, West M. Myelin proteolipid protein: function in myelin structure is distinct from its role in oligodendrocyte development. Dev Neurosci. 1998;20:533–539.
   PubMed Web of Science ®Google Scholar
• Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 2001;81:871–927.
   PubMed Web of Science ®Google Scholar
• Michalski J-P KR. Oligodendrocytes in a nutshell. Front Cell Neurosci. 2015;9:1–11.
   PubMed Web of Science ®Google Scholar
• Kessaris N, Fogarty M, Iannarelli P, et al. Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nat Neurosci. 2006;9:173–179.
   PubMed Web of Science ®Google Scholar
• Ge W-P, Miyawaki A, Gage F, et al. Local generation of glia is a major astrocyte source in postnatal cortex. Nature. 2012;484:376–380.
   PubMed Web of Science ®Google Scholar
• Genoud S, Lappe-Siefke C, Goebbels S, et al. Notch1 control of oligodendrocyte differentiation in the spinal cord. J Cell Biol. 2002;158:709–718.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Argaw AT, Gurfein BT, et al. Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc Natl Acad Sci. 2009;106:19162–19167.
   PubMed Web of Science ®Google Scholar
• Emery B. Regulation of oligodendrocyte differentiation and myelination. Science. 2010;330:779–782.
   PubMed Web of Science ®Google Scholar
• Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443–448.
   PubMed Web of Science ®Google Scholar
• Saab AS, Tzvetanova ID, Nave KA. The role of myelin and oligodendrocytes in axonal energy metabolism. Curr Opin Neurobiol. 2013;23:1065–1072.
   PubMed Web of Science ®Google Scholar
• Halestrap AP, Wilson MC. The monocarboxylate transporter family-role and regulation. IUBMB Life. 2012;64:109–119.
   PubMed Web of Science ®Google Scholar
• Crawford AH, Tripathi RB, Foerster S, et al. Pre-existing mature oligodendrocytes do not contribute to remyelination following toxin-induced spinal cord demyelination. Am J Pathol. 2016;186:511–516.
   PubMed Web of Science ®Google Scholar
• Rodriguez M. Multiple sclerosis: basic concepts and hypothesis. Mayo Clin Proc. 1989;64:570–576.
   PubMed Web of Science ®Google Scholar
• Scolding N, Franklin R, Stevens S, et al. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain. 1998;121:2221–2228.
   PubMed Web of Science ®Google Scholar
• Díez-Revuelta N, Higuero AM, Velasco S, et al. Neurons define non-myelinated axon segments by the regulation of galectin-4-containing axon membrane domains. Sci Rep. 2017;7:1–13.
   PubMed Web of Science ®Google Scholar
• Stancic M, Slijepcevic D, Nomden A, et al. Galectin-4, a novel neuronal regulator of myelination MIRJANA. Glia. 2012;60:919–935.
   PubMed Web of Science ®Google Scholar
• Charlotte GHM, de Jong M, Stancic M, et al. Galectin-4, a negative regulator of oligodendrocyte differentiation, is persistently present in axons and microglia/macrophages. Synthesis (Stuttg). 2018;77:0527–0536.
   Google Scholar
• Chen MS, Huber AB, Van Der Haar MED, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000;403:434–439.
   PubMed Web of Science ®Google Scholar
• Satoh JI, Onoue H, Arima K, et al. Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis. J Neuropathol Exp Neurol. 2005;64:129–138.
   PubMed Web of Science ®Google Scholar
• Kim M, Kang J, Theotokis P, et al. Can we design a nogo receptor-dependent cellular therapy to target MS? Cells. 2018;8:1.
   Web of Science ®Google Scholar
• Watzlawik JO, Warrington AE, Rodriguez M. PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation. PLoS One. 2013;8:1–16.
   Web of Science ®Google Scholar
• Nastasijevic B, Wright BR, Smestad J, et al. Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. PLoS One. 2012;7:1–8.
   Google Scholar
• Perschbacher K, Smestad JA, Peters JP, et al. Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice. Nucleic Acid Ther. 2015;25:11–19.
   PubMed Web of Science ®Google Scholar
• Wilbanks B, Smestad J, Heider RM, et al. Optimization of a 40-mer anti-myelin aptamer identifies a 20-mer with enhanced properties for potential multiple sclerosis therapy. Nucleic Acid Ther. 2019; in press.
   Google Scholar
• Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflammation. 2014;1:e18.
   PubMedGoogle Scholar
• McCroskery P, Selmaj K, Fernandez O, et al. Safety and tolerability of opicinumab in relapsing multiple sclerosis: the phase 2b SYNERGY trial (P5.369). Neurology. 2017;88.
   Google Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189–199.
   PubMed Web of Science ®Google Scholar
• Ruggieri S, Tortorella C, Anti Lingo GC. 1 (Opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis. Expert Rev Neurother. 2017;91:399–404.
   Google Scholar
• Fan H, Zhao JG, Yan JQ, et al. Effect of Notch1 gene on remyelination in multiple sclerosis in mouse models of acute demyelination. J Cell Biochem. 2018;119:9284–9294.
   PubMed Web of Science ®Google Scholar
• Mei F, Fancy SPJ, Shen YAA, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014;20:954–960.
   PubMed Web of Science ®Google Scholar
• Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390:2481–2489.
   PubMed Web of Science ®Google Scholar
• Kawabata S, Takano M, Numasawa-Kuroiwa Y, et al. Grafted human iPS cell-derived oligodendrocyte precursor cells contribute to robust remyelination of demyelinated axons after spinal cord injury. Stem Cell Reports. 2016;6:1–8.
   PubMed Web of Science ®Google Scholar
• Salewski RP, Mitchell RA, Li L, et al. Transplantation of induced pluripotent stem cell-derived neural stem cells mediate functional recovery following thoracic spinal cord injury through remyelination of axons. Stem Cells Transl Med. 2015;4:743–754.
   PubMed Web of Science ®Google Scholar
• Jaramillo-Merchán J, Jones J, Ivorra JL, et al. Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model. Cell Death Dis. 2013;4:e779.
   PubMed Web of Science ®Google Scholar
• Dolati S, Babaloo Z, Jadidi-Niaragh F, et al. Multiple sclerosis: therapeutic applications of advancing drug delivery systems. Biomed Pharmacother. 2017;86:343–353.
   PubMed Web of Science ®Google Scholar